Literature DB >> 35745764

Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents.

Paola Oliva1, Romeo Romagnoli1, Barbara Cacciari1, Stefano Manfredini2, Chiara Padroni3, Andrea Brancale4, Salvatore Ferla5, Ernest Hamel6, Diana Corallo7, Sanja Aveic7, Noemi Milan8, Elena Mariotto8,9, Giampietro Viola8,9, Roberta Bortolozzi8,9.   

Abstract

Two different series of fifty-two compounds, based on 3',4',5'-trimethoxyaniline (7a-ad) and variably substituted anilines (8a-v) at the 7-position of the 2-substituted-[1,2,4]triazolo [1,5-a]pyrimidine nucleus, had moderate to potent antiproliferative activity against A549, MDA-MB-231, HeLa, HT-29 and Jurkat cancer cell lines. All derivatives with a common 3-phenylpropylamino moiety at the 2-position of the triazolopyrimidine scaffold and different halogen-substituted anilines at its 7-position, corresponding to 4'-fluoroaniline (8q), 4'-fluoro-3'-chloroaniline (8r), 4'-chloroaniline (8s) and 4'-bromoaniline (8u), displayed the greatest antiproliferative activity with mean IC50's of 83, 101, 91 and 83 nM, respectively. These four compounds inhibited tubulin polymerization about 2-fold more potently than combretastatin A-4 (CA-4), and their activities as inhibitors of [3H]colchicine binding to tubulin were similar to that of CA-4. These data underlined that the 3',4',5'-trimethoxyanilino moiety at the 7-position of the [1,2,4]triazolo [1,5-a]pyrimidine system, which characterized compounds 7a-ad, was not essential for maintaining potent antiproliferative and antitubulin activities. Compounds 8q and 8r had high selectivity against cancer cells, and their interaction with tubulin led to the accumulation of HeLa cells in the G2/M phase of the cell cycle and to apoptotic cell death through the mitochondrial pathway. Finally, compound 8q significantly inhibited HeLa cell growth in zebrafish embryos.

Entities:  

Keywords:  [1,2,4]triazolo [1,5-a]pyrimidine; antimitotic agents; antiproliferative activity; structure–activity relationship; tubulin polymerization

Year:  2022        PMID: 35745764      PMCID: PMC9230136          DOI: 10.3390/pharmaceutics14061191

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.525


  58 in total

Review 1.  Microtubule-targeted agents: when mitochondria become essential to chemotherapy.

Authors:  A Rovini; A Savry; D Braguer; M Carré
Journal:  Biochim Biophys Acta       Date:  2011-01-07

Review 2.  Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.

Authors:  Wenlong Li; Honghao Sun; Shengtao Xu; Zheying Zhu; Jinyi Xu
Journal:  Future Med Chem       Date:  2017-09-20       Impact factor: 3.808

Review 3.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Authors:  Rumani Singh; Anthony Letai; Kristopher Sarosiek
Journal:  Nat Rev Mol Cell Biol       Date:  2019-03       Impact factor: 94.444

4.  Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines.

Authors:  Xian-Sen Huo; Xie-Er Jian; Jie Ou-Yang; Lin Chen; Fang Yang; Dong-Xin Lv; Wen-Wei You; Jin-Jun Rao; Pei-Liang Zhao
Journal:  Eur J Med Chem       Date:  2021-04-16       Impact factor: 6.514

5.  Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b]thiophene derivatives as a novel class of antiproliferative agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Carlota Lopez Cara; Ernest Hamel; Giuseppe Basso; Roberta Bortolozzi; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2010-10-08       Impact factor: 6.514

Review 6.  The Elephant in the Room: The Role of Microtubules in Cancer.

Authors:  Luca Cirillo; Monica Gotta; Patrick Meraldi
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.

Authors:  Changwen Deng; Jingjing Zhao; Shixin Zhou; Jiebin Dong; Jixiang Cao; Junshuang Gao; Yun Bai; Hongkui Deng
Journal:  Mol Ther       Date:  2019-10-18       Impact factor: 11.454

8.  Correction: McLoughlin, E.C.; O'Boyle, N.M. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. Pharmaceuticals 2020, 13, 8.

Authors:  Eavan C McLoughlin; Niamh M O'Boyle
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-20

9.  Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time.

Authors:  Audrey Fohlen; Karim Bordji; Eric Assenat; Céline Gongora; Céline Bazille; Jérémy Boulonnais; Mikaël Naveau; Cécile Breuil; Elodie A Pérès; Myriam Bernaudin; Boris Guiu
Journal:  Pharmaceuticals (Basel)       Date:  2021-07-01

Review 10.  The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review.

Authors:  Kai Liu; Minying Zheng; Rui Lu; Jiaxing Du; Qi Zhao; Zugui Li; Yuwei Li; Shiwu Zhang
Journal:  Cancer Cell Int       Date:  2020-06-03       Impact factor: 5.722

View more
  1 in total

1.  Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities.

Authors:  Romeo Romagnoli; Paola Oliva; Filippo Prencipe; Stefano Manfredini; Federica Budassi; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Diana Corallo; Sanja Aveic; Lorenzo Manfreda; Elena Mariotto; Roberta Bortolozzi; Giampietro Viola
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.